Children with obsessive-compulsive disorder (OCD) are often prescribed antidepressant drugs (serotonin reuptake inhibitors – SRI), but many only partially respond to this treatment. This randomised controlled trial conducted by researchers from the University of Pennsylvania School of Medicine, examined the effects of augmenting the antidepressant medication with cognitive behaviour therapy (CBT). The trial was quite [read the full story…]
Around 1% of the population have autism. There are a number of treatments available for the condition, including learning and development techniques, as well as medical interventions. However, there is little consensus about which drug treatments are most effective. A team of researchers from Nashville have recently published two systematic reviews in the Pediatrics journal, [read the full story…]
Research shows that using antidepressants (serotonin reuptake inhibitors, SRIs) to treat obsessive compulsive disorder (OCD) in young people is sometimes problematic. Patients often do not respond to the drugs and so other therapies are necessary to augment the treatment. One such therapy is CBT (cognitive behavioural therapy). This 12-week randomised controlled trial took 124 paediatric [read the full story…]
There are a number of cross-sectional studies that investigate antidepressant use in teenagers and young adults. These are interesting, but because they don’t tend to follow-up study participants prospectively over a long period of time, there is only so much we can learn from them. However, now researchers in Finland have published a study that [read the full story…]
Teenagers with depression sometimes do not respond to treatment with SSRI antidepressants and this inevitably leads to a higher cost of treatment. This randomised controlled trial (conducted by researchers from Kaiser Permanente Northwest in Portland, Oregon) set out to evaluate the incremental cost-effectiveness over 24 weeks of combined cognitive behavior therapy plus switch to a different antidepressant [read the full story…]
The debate about antidepressant use and suicide in young people rages on. A new meta-analysis of placebo-controlled paroxetine trials has been published in the Journal of Clinical Psychiatry by a research team at GlaxoSmithKline (the company who make the drug also known as Aropax, Paxil and Seroxat) in Pennsylvania. This kind of drug company conducted [read the full story…]
